PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has appointed Kamil Ali-Jackson, Esq. to its Board of Directors. Ms. Ali-Jackson will be a member of the Board’s audit committee.
“We are very pleased to welcome Kamil to the Board of Directors and look forward to her insights and contributions as we continue to progress the company’s Versamune®-based clinical and preclinical pipeline and grow PDS into a leading immuno-oncology company. Kamil’s extensive legal experience, particularly with financial transactions, strategic alliances, and development and commercialization transactions, will be an invaluable asset to the team and help guide the Company,” commented Steve Glover, Chairman of the Board of PDS. “With our successful financing complete we look forward to initiating three Phase 2 clinical trials for our lead product candidate PDS0101 over the coming months.”
Kamil Ali-Jackson, Esq. has more than 30 years of experience as legal counsel in the life sciences industry with public and private specialty pharmaceutical, biotech and biopharmaceutical companies. Ms. Ali-Jackson has extensive domestic and international experience with strategic alliances, drug development and commercialization collaborations and M&A transactions. She is a co-founder of Aclaris Therapeutics, Inc. and has served as Chief Legal Officer since its inception in 2012. In addition, since 2013, she has served as Chief Legal Officer of NeXeption II, LLC and its affiliates. Previously, Kamil served as Chief Legal Officer of Ralexar Therapeutics, Inc. (formerly known as Alexar Therapeutics Inc.). She has also served as legal counsel and as a licensing business executive for large pharmaceutical companies, including Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., and Endo Pharmaceuticals, Inc.
Ms. Ali-Jackson holds her Juris Doctorate from Harvard Law School in addition to a Bachelor of Arts degree in politics from Princeton University. She was a 2011 Philadelphia Business Journal Woman of Distinction winner. She has served on several nonprofit boards and is currently on the board of Rosemont College, a private liberal arts college located in Pennsylvania.
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
PDS Biotech’s lead candidate, PDS0101, combines the utility of the Versamune® platform with targeted antigens in HPV-expressing cancers. In partnership with Merck, PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA® to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with the chemoradiotherapy, which is the standard of care.
